Trials / Completed
CompletedNCT01123772
Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers
Phase I, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation Study to Evaluate Tolerability, Safety & PK of BID Topical Ocular Application of INO-8875 in Healthy Older-Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Inotek Pharmaceuticals Corporation · Industry
- Sex
- All
- Age
- 35 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate how tolerable and safe it is to give INO-8875 eye drops at different concentrations to normal older healthy adult volunteers for two weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INO-8875 | eye drops for 14 days in one eye |
| OTHER | Placebo control | Matched placebo |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2010-05-14
- Last updated
- 2012-04-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01123772. Inclusion in this directory is not an endorsement.